Arthritis, Rheumatoid Clinical Trial
Official title:
A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.
Rheumatoid arthritis (RA) is a rheumatic inflammatory synovitis characterized by pain and
joint swelling as well as thickening synovial (pannus) lesions that are responsible of
osteocartilaginous and tendon damage. It evolves in spurts or long and variable intensity
interspersed with remissions.
The effectiveness of treatment is based on the proportion of patients who achieve a certain
degree of improvement over the initial level of various parameters such as response criteria
ACR 20, 50 or 70% or EULAR based on the evolution of DAS 28 or DAS 44. These response
criteria are now well validated but do not fully take into account the improvement of the
patient's condition. In contrast, there is no questionnaire to identify the proportion of
patients whose RA worsened between the medical visits. Such a questionnaire is necessary to
detect flares outbreaks in daily practice and in randomized clinical trials, follow-up
studies or longitudinal studies after drugs marketing to detect a reversal of disease
activity.
Both STPR group and OMERACT group have each developed such a new self-administered
questionnaire (FLARE and OM-RA-FLARE) to detect the flare- in RA patients.
The objective of this study is to validate the questionnaires FLARE and OM-RA-FLARE among RA
patients using the methodology advocated by the OMERACT in terms of validity (truth),
discriminating power (discrimination) and feasibility
There will be 6 months of follow up including 3 medical visits for each patients:
- M0 (medical visit for inclusion)
- follow up between M0 - M3
- M3 (medical visit at 3 months after inclusion)
- follow up between M3 - M6
- M6 (medical visit at 6 months after inclusion)
At the inclusion visit (M0), after the verification of inclusion and non-inclusion criteria,
the following information will be collected:
- Socio-demographical data : age, sex, level of education (primary, secondary, college,
university), occupational category (INSEE in 6 categories)
- Items of the ACR 1987 and ACR/EULAR 2010;
- Length of the RA
- Erosive or not (presence Yes / no)
- IgM rheumatoid factor (presence Yes / No)
- Anti CCP antbodies (presence Yes / No)
During follow-up visits (M3 and M6), the elements collected are:
1. by the study technician (TEC)
- the inflammatory activity index, evaluated by patient (RAPID-3);
- the functional limitations index (HAQ);
- the PASS questionnaire;
- the OM-RA-FLARE questionnaire;
- the FLARE questionnaire.
2. by the doctor :
- elements of DAS 28, this includes a blood test that will be done in the city or in
the hospital ;
- the doctor's decision at the end of the consultation, in terms of :
- DMRADs: continuing the treatment, decreasing or increasing the dose, changing
it due to its ineffectiveness, changing it due to patients' intolerance.
- Symptomatic treatments: continuing corticosteroids, increase the dose of
corticosteroids, corticosteroid infiltration.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 |